Also found in: Dictionary.
Pharmacologic class: Peripherally selective piperidine, selective histamine1-receptor antagonist
Therapeutic class: Antihistamine (nonsedating type), second-generation
Pregnancy risk category C
Blocks effects of histamine at peripheral histamine1-receptor sites, decreasing allergy signs and symptoms
Capsules: 60 mg
Oral suspension: 30 mg/5 ml (6 mg/ml)
Tablets: 30 mg, 60 mg, 180 mg
Tablets (orally disintegrating): 30 mg
Indications and dosages
➣ Seasonal allergic rhinitis; chronic idiopathic urticaria
Adults and children age 12 and older: 60 mg P.O. b.i.d. or 180 mg once daily (conventional tablets)
Children ages 6 to 11: 30 mg P.O. b.i.d. (conventional tablets or ODT tablets)
➣ Seasonal allergic rhinitis
Children ages 2 to 11: 30 mg P.O. b.i.d. (oral suspension and ODT)
➣ Chronic idiopathic urticaria
Children ages 6 months to less than 2 years: 15 mg P.O. b.i.d.(oral suspension and ODT)
• Renal impairment
• Hypersensitivity to drug, terfenadine, or their components
Use cautiously in:
• renal impairment
• concurrent ketoconazole or erythromycin therapy
• elderly patients
• pregnant or breastfeeding patients.
• Give capsules and conventional tablets with water; don't give with apple, orange, or grapefruit juice.
• Don't remove orally disintegrating tablets from original blister package until time of administration.
• Administer orally disintegrating tablets on an empty stomach; allow tablets to disintegrate on the tongue and then have patient swallow tablets with or without water.
• Don't break or use partial orally disintegrating tablets
• Know that orally disintegrating tablets contain phenylalanine.
• Don't give antacids within 2 hours of fexofenadine.
CNS: drowsiness, fatigue, headache
EENT: otitis media
GI: nausea, dyspepsia
Respiratory: upper respiratory tract infection
Other: viral infection
Drug-drug. Antacids containing aluminum and magnesium: decreased absorption and efficacy of fexofenadine
Drug-diagnostic tests. Skin allergy tests: false-negative results
Drug-food. Apple, orange, and grapefruit juice: decreased absorption and efficacy of fexofenadine
• Monitor renal function.
• Watch for signs and symptoms of viral infection.
• Instruct patient to take conventional tablets with water, and not with apple, orange, or grapefruit juice.
• Instruct patient not to remove orally disintegrating tablets from original blister package until time of administration.
• Instruct patient to take orally disintegrating tablets on an empty stomach at least 1 hour before or 2 hours after a meal, to allow tablet to disintegrate on the tongue, and then to swallow with or without water. Advise patient not to chew tablets.
• Tell patient not to break or use partial orally disintegrating tablets.
• Tell patient to stop taking drug 4 days before diagnostic skin tests, to avoid interference with test results.
• Advise patient to report signs or symptoms of viral infection, especially upper respiratory tract infection.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Advise female patient to inform prescriber if she is pregnant or breastfeeding.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.